Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
18hon MSN
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter.
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...
SEC Filings provided by EDGAR Online, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback